Michael Parini: Thanks, Pam. And maybe, I think the third question had to do with our cash runway. We have taken a number of steps Dae Gon as you saw in our release to extend our cash runway into Q2 2024, and we absolutely are hyper focused on spend right now as you can imagine. And so, we are looking forward to dosing patients and really driving data in the third quarter of this year, which we think will be an important catalyst for the company. Beyond that, we continue to work on operational efficiency and certainly are open to business development and other opportunities, but nothing specific to say beyond that.
Dae Gon Ha: Thanks so much.
Operator: Thank you. We will now take the next question. It comes from the line of Yun Zhong from BTIG. Please go ahead. Your line is open.
Yun Zhong: Hi. Good morning. Thank you very much for taking the questions. I wanted to confirm that you are going to use the same immunosuppression regimen in the Gaucher study, and also I assume those patients will be allowed to discontinue ERT or SRT at some point once they have met certain criteria?
Michael Parini: Hey, Yun. Thanks for the question. Appreciate it. Maybe Pam, do you want to comment on the immune suppression regimen we’re using in 201 and GALILEO study and how ERT or SRT cessation works?
Pam Foulds: Great. Sure. So, the Gaucher trial has the same new management algorithm or recipe, if you will. And importantly, within all of our clinical trials it does allow for individualization with the physicians and in discussion with our medical monitors here at Freeline. So, importantly, patients, a number of weeks, about 3 weeks into their treatment, they have the ability to start prophylactic prednisolone, as well as tacrolimus. Importantly, as I said too, that all patients, including those in GALILEO, will have the ability with their physicians talking with their medical monitors determine what is the best path for each individual patient. And that could be slower tapering, faster tapering removal of the medication completely.
So, there’s a lot of variability that is going to be allowed and is allowed already in these clinical trials. As far as removal of their current therapies, the protocol does call for that to occur. What it does €“ what we have made the change a number of years ago was to allow for a short period of overlap to ensure that there is coverage during those early weeks. At about the 3-week time point, the physician then will be looking to understand based on the enzyme levels, the GK’s enzyme levels to withdraw ERT or SRT at that point.
Yun Zhong: Okay. A follow-up question then. Looks like it’s €“ at this point, it’s still an ex-U.S. study. So, do you have an IND open in the U.S. please? Thank you.
Michael Parini: Yes. Thank you. We do have an IND open in the U.S. And we have multiple sites coming online. I think we have one site that’s fully approved and screening patients and then we have I think three additional sites that we’re bringing online really later this month and next month. So, this is a truly global study.
Yun Zhong: Okay, great. Thank you very much.
Operator: Thank you. There are no further questions at this time. I would like to hand back over to the speakers for final remarks.
Michael Parini: Well, thank you everybody for participating in today’s call. Before we close, I would like to thank the Freeline team, as well as our study investigators and the patients who are participating in our trials, the IR team, and management team are standing by. If you have additional questions, just reach out to Naomi. Thanks, everybody.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
